Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Florent Happe"'
Autor:
Géraldine Poénou, Emmanuel Tolédano, Hélène Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, Isabelle Mahé
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
IntroductionAnticoagulant is the cornerstone of the management of VTE at the cost of a non-negligible risk of bleeding. Reliable and validated clinical tools to predict thromboembolic and hemorrhagic events are crucial for individualized decision-mak
Externí odkaz:
https://doaj.org/article/7f100e4aa648408bbf1ec0e6a5c498db
Autor:
Marilucy Lopez-Sublet, Bénédicte Giroux Leprieur, Rosaline Nguyen, Rashida Sariya, Benjamin Magnan, Florent Happe, Robin Dhote, Claire Mounier Vehier
Publikováno v:
La Presse Médicale Formation. 3:355-358
Autor:
Mahé, Hélène Helfer, Yara Skaff, Florent Happe, Sadji Djennaoui, Jean Chidiac, Géraldine Poénou, Marc Righini, Isabelle
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 3031
Venous thromboembolic disease (VTE) is a common complication in cancer patients. The currently recommended VTE diagnostic approach involves a step-by-step algorithm, which is based on the assessment of clinical probability, D-dimer measurement, and/o
Autor:
Marilucy Lopez-Sublet, Bénédicte Giroux Leprieur, Cynthia Soare, Rosaline Nguyen, Rashida Sariya, Benjamin Magnan, Florent Happe, Robin Dhote, Claire Mounier Vehier
Publikováno v:
La Presse Médicale Formation. 3:476
Autor:
Géraldine Poénou, Emmanuel Tolédano, Hélène Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, Isabelle Mahé
Publikováno v:
Cancers. 14:1937
Patients with venous thromboembolism events (VTE) in the context of cancer should receive anticoagulants as long as the cancer is active. Therefore, a tailor-made anticoagulation strategy should rely on an individualized risk assessment model (RAM) o